Last but not least, a few studies have demonstrated that the 124I-codrituzumab compound, an antibody targeting glypican 3 (a cell-surface glycoprotein overexpressed in cancerous tissue), is able to detect tumor localization in most patients with HCC [75,111]. The gene discussed is GPC3; the disease is hepatocellular carcinoma.